Stanislav V. Ermolaev , Aleksandr N. Vasiliev , Aino K. Skasyrskaya , Elena V. Lapshina , Daria R. Khaliullina , Olga N. Libanova
{"title":"用于直接合成 213Bi 标记生物共轭物的 225Aс/213Bi 发生器","authors":"Stanislav V. Ermolaev , Aleksandr N. Vasiliev , Aino K. Skasyrskaya , Elena V. Lapshina , Daria R. Khaliullina , Olga N. Libanova","doi":"10.1016/j.nucmedbio.2024.108975","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div><sup>213</sup>Bi is a short-lived radionuclide currently trialed for alpha therapy of various oncological diseases. A serious obstacle to the wide medical use is decay losses of <sup>213</sup>Bi during a conventional synthesis of radiopharmaceuticals. In this work, we aimed to develop a two-column <sup>225</sup>Aс/<sup>213</sup>Bi generator providing the accumulation of <sup>213</sup>Bi separately from the parent <sup>225</sup>Ac <em>via</em> continuous circular separation and decay of intermediate <sup>221</sup>Fr. When attaining the transient equilibrium, <sup>213</sup>Bi could be promptly extracted from the generator with an appropriate complexing agent, including chelator-protein bioconjugates.</div></div><div><h3>Methods</h3><div>Sorption behavior of Bi(III) ions onto the cross-linked dextran gel Sephadex G-25 was studied from solutions of hydrochloric and nitric acid, and from sodium chloride, sodium acetate and DTPA solutions. A bifunctional chelating agent p-SCN-Bn-DTPA was conjugated to an antibody Nimotuzumab specific to the epidermal growth factor receptor, and the procedure of <sup>207,213</sup>Bi-DTPA-Nimotuzumab synthesis in the dextran gel medium was developed. The parameters of <sup>225</sup>Aс/<sup>213</sup>Bi generator system were evaluated.</div></div><div><h3>Results</h3><div>The weight distribution ratios of Bi(III) adsorbed onto the Sephadex G-25 gel were obtained. Up to 85 % of <sup>213</sup>Bi was accumulated in the second Sephadex-filled column of <sup>225</sup>Aс/<sup>213</sup>Bi generator after four-hour circulation of 0.15 M NaCl (pH 5.5) solution. Having passed the solution of DTPA-Nimotuzumab bioconjugate through the second column, a fraction of <sup>213</sup>Bi-DTPA-Nimotuzumab radioimmunoconjugate was produced with the radiochemical yield of 64 % ± 3 % (<em>n</em> = 6). High radionuclidic and radiochemical purity of product was achieved.</div></div><div><h3>Conclusions</h3><div>The circulating <sup>225</sup>Aс/<sup>213</sup>Bi generator provides a <sup>213</sup>Bi-labeled bioconjugate as a final product. While a conventional synthesis route including generator milking, bioconjugate labeling and size-exclusion purification takes >20 min, the duration of <sup>213</sup>Bi-DTPA-Nimotuzumab production by the method proposed in this work is reduced to 6–8 min.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"140 ","pages":"Article 108975"},"PeriodicalIF":3.6000,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"225Aс/213Bi generator for direct synthesis of 213Bi-labeled bioconjugates\",\"authors\":\"Stanislav V. Ermolaev , Aleksandr N. Vasiliev , Aino K. Skasyrskaya , Elena V. Lapshina , Daria R. Khaliullina , Olga N. Libanova\",\"doi\":\"10.1016/j.nucmedbio.2024.108975\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div><sup>213</sup>Bi is a short-lived radionuclide currently trialed for alpha therapy of various oncological diseases. A serious obstacle to the wide medical use is decay losses of <sup>213</sup>Bi during a conventional synthesis of radiopharmaceuticals. In this work, we aimed to develop a two-column <sup>225</sup>Aс/<sup>213</sup>Bi generator providing the accumulation of <sup>213</sup>Bi separately from the parent <sup>225</sup>Ac <em>via</em> continuous circular separation and decay of intermediate <sup>221</sup>Fr. When attaining the transient equilibrium, <sup>213</sup>Bi could be promptly extracted from the generator with an appropriate complexing agent, including chelator-protein bioconjugates.</div></div><div><h3>Methods</h3><div>Sorption behavior of Bi(III) ions onto the cross-linked dextran gel Sephadex G-25 was studied from solutions of hydrochloric and nitric acid, and from sodium chloride, sodium acetate and DTPA solutions. A bifunctional chelating agent p-SCN-Bn-DTPA was conjugated to an antibody Nimotuzumab specific to the epidermal growth factor receptor, and the procedure of <sup>207,213</sup>Bi-DTPA-Nimotuzumab synthesis in the dextran gel medium was developed. The parameters of <sup>225</sup>Aс/<sup>213</sup>Bi generator system were evaluated.</div></div><div><h3>Results</h3><div>The weight distribution ratios of Bi(III) adsorbed onto the Sephadex G-25 gel were obtained. Up to 85 % of <sup>213</sup>Bi was accumulated in the second Sephadex-filled column of <sup>225</sup>Aс/<sup>213</sup>Bi generator after four-hour circulation of 0.15 M NaCl (pH 5.5) solution. Having passed the solution of DTPA-Nimotuzumab bioconjugate through the second column, a fraction of <sup>213</sup>Bi-DTPA-Nimotuzumab radioimmunoconjugate was produced with the radiochemical yield of 64 % ± 3 % (<em>n</em> = 6). High radionuclidic and radiochemical purity of product was achieved.</div></div><div><h3>Conclusions</h3><div>The circulating <sup>225</sup>Aс/<sup>213</sup>Bi generator provides a <sup>213</sup>Bi-labeled bioconjugate as a final product. While a conventional synthesis route including generator milking, bioconjugate labeling and size-exclusion purification takes >20 min, the duration of <sup>213</sup>Bi-DTPA-Nimotuzumab production by the method proposed in this work is reduced to 6–8 min.</div></div>\",\"PeriodicalId\":19363,\"journal\":{\"name\":\"Nuclear medicine and biology\",\"volume\":\"140 \",\"pages\":\"Article 108975\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2024-11-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nuclear medicine and biology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S096980512400101X\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuclear medicine and biology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S096980512400101X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
225Aс/213Bi generator for direct synthesis of 213Bi-labeled bioconjugates
Background
213Bi is a short-lived radionuclide currently trialed for alpha therapy of various oncological diseases. A serious obstacle to the wide medical use is decay losses of 213Bi during a conventional synthesis of radiopharmaceuticals. In this work, we aimed to develop a two-column 225Aс/213Bi generator providing the accumulation of 213Bi separately from the parent 225Ac via continuous circular separation and decay of intermediate 221Fr. When attaining the transient equilibrium, 213Bi could be promptly extracted from the generator with an appropriate complexing agent, including chelator-protein bioconjugates.
Methods
Sorption behavior of Bi(III) ions onto the cross-linked dextran gel Sephadex G-25 was studied from solutions of hydrochloric and nitric acid, and from sodium chloride, sodium acetate and DTPA solutions. A bifunctional chelating agent p-SCN-Bn-DTPA was conjugated to an antibody Nimotuzumab specific to the epidermal growth factor receptor, and the procedure of 207,213Bi-DTPA-Nimotuzumab synthesis in the dextran gel medium was developed. The parameters of 225Aс/213Bi generator system were evaluated.
Results
The weight distribution ratios of Bi(III) adsorbed onto the Sephadex G-25 gel were obtained. Up to 85 % of 213Bi was accumulated in the second Sephadex-filled column of 225Aс/213Bi generator after four-hour circulation of 0.15 M NaCl (pH 5.5) solution. Having passed the solution of DTPA-Nimotuzumab bioconjugate through the second column, a fraction of 213Bi-DTPA-Nimotuzumab radioimmunoconjugate was produced with the radiochemical yield of 64 % ± 3 % (n = 6). High radionuclidic and radiochemical purity of product was achieved.
Conclusions
The circulating 225Aс/213Bi generator provides a 213Bi-labeled bioconjugate as a final product. While a conventional synthesis route including generator milking, bioconjugate labeling and size-exclusion purification takes >20 min, the duration of 213Bi-DTPA-Nimotuzumab production by the method proposed in this work is reduced to 6–8 min.
期刊介绍:
Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized.
These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field.
Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.